CMPX vs. ETNB, AUPH, GYRE, MLYS, WVE, PAHC, ARDX, COLL, NTLA, and RCUS
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Mineralys Therapeutics (MLYS), Wave Life Sciences (WVE), Phibro Animal Health (PAHC), Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.
Compass Therapeutics vs.
Compass Therapeutics (NASDAQ:CMPX) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.
Compass Therapeutics' return on equity of -32.37% beat 89bio's return on equity.
In the previous week, 89bio had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 5 mentions for 89bio and 2 mentions for Compass Therapeutics. 89bio's average media sentiment score of 1.74 beat Compass Therapeutics' score of 1.45 indicating that 89bio is being referred to more favorably in the news media.
Compass Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Compass Therapeutics has higher revenue and earnings than 89bio. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics currently has a consensus target price of $13.13, indicating a potential upside of 525.00%. 89bio has a consensus target price of $26.43, indicating a potential upside of 173.87%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Compass Therapeutics is more favorable than 89bio.
89bio received 67 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 81.36% of users gave Compass Therapeutics an outperform vote while only 62.50% of users gave 89bio an outperform vote.
68.4% of Compass Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by insiders. Comparatively, 2.6% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Compass Therapeutics beats 89bio on 12 of the 17 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMPX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CMPX Stock Free CMPX Stock Alerts